While it claims over 760,000 lives each year, making it the world's third deadliest cancer, the story of gastric cancer is one of stark geographic disparities and preventable risk factors.
Key Takeaways
- In 2020, gastric cancer accounted for 1,089,103 new cases worldwide, making it the fifth most common cancer globally
- Gastric cancer incidence rate is 11.1 per 100,000 globally in 2022 estimates, with higher rates in Eastern Asia at 32.4 per 100,000
- In the United States, there were 26,500 new cases of stomach cancer estimated in 2023
- Helicobacter pylori infection prevalence correlates with 80% of gastric cancer cases globally
- Smoking increases gastric cancer risk by 1.5-2 fold, with 17% of cases attributable in men
- High salt intake (>5g/day) raises gastric cancer risk by 1.7 times per WHO estimates
- Early satiety occurs in 60-80% of advanced gastric cancer patients
- Unintentional weight loss >10% body weight in 3 months seen in 70% cases
- Endoscopy detects 90-95% of gastric cancers, with biopsy confirmation
- 5-year survival for stage I gastric cancer post-resection is 70-90%
- Perioperative chemotherapy (FLOT regimen) improves OS by 10% vs surgery alone
- Trastuzumab + chemo in HER2+ advanced disease median OS 13.8 vs 11.1 months
- Global gastric cancer mortality 769,000 deaths in 2020, third leading cancer killer
- 5-year relative survival US all stages 36.3% (2013-2019), localized 75.5%
- In Japan, overall 5-yr survival 64.3% due to screening (2014-2016)
Gastric cancer is a leading global killer, with highest rates in Eastern Asia.
Epidemiology
1In 2020, gastric cancer accounted for 1,089,103 new cases worldwide, making it the fifth most common cancer globally
Verified2Gastric cancer incidence rate is 11.1 per 100,000 globally in 2022 estimates, with higher rates in Eastern Asia at 32.4 per 100,000
Verified3In the United States, there were 26,500 new cases of stomach cancer estimated in 2023
Verified4Age-standardized incidence rate for gastric cancer in Japan is 27.5 per 100,000 for males in 2020
Directional5Gastric cancer prevalence is highest in Mongolia at 33.1 per 100,000 in 2020
Single source6In Europe, gastric cancer incidence has declined by 3.7% annually from 1990-2019
Verified7US gastric cancer incidence among non-Hispanic Blacks is 50% higher than non-Hispanic Whites at 7.1 vs 4.7 per 100,000
Verified8Globally, gastric cardia cancer incidence is rising in high-income countries by 2.2% per year
Verified9In China, gastric cancer represents 25.8% of all cancer cases in men aged 50-74
Directional10Korean males have the highest gastric cancer incidence at 39.6 per 100,000 in 2018
Single source11Gastric cancer is the third leading cause of cancer death worldwide with 769,000 deaths in 2020
Verified12Incidence of gastric cancer in Latin America averages 15-20 per 100,000, highest in Chile at 34.1
Verified13In India, gastric cancer incidence is 3.6 per 100,000 but rising in urban areas
Verified14Eastern Europe has gastric cancer rates of 18.2 per 100,000 for males
Directional15Global gastric cancer burden projected to reach 1.3 million new cases by 2040
Single source16In 2022 GLOBOCAN, Mongolia had highest gastric cancer ASMR 27.2 per 100,000
Verified17Female global incidence 8.7 per 100,000 vs male 15.7 in 2020
Verified18Brazil gastric cancer incidence 12.5 per 100,000 average
Verified19Russia mortality rate 17.4 per 100,000 males 2020
Directional20Incidence peaks age 70-74 globally, 50.2 per 100,000 men
Single source21Australia incidence low at 4.5 per 100,000 due to H.pylori decline
Verified22Iran high rate 17.9 per 100,000, second most common GI cancer
Verified23UK incidence 6.3 per 100,000, cardia subtype rising
Verified24Nigeria low incidence 4.1 but poor data quality
Directional25Vietnam incidence 15.6 per 100,000, fourth common cancer
Single sourceEpidemiology Interpretation
While it remains a grim global heavyweight—ranking fifth in frequency but third in mortality—the story of gastric cancer is one of stark and stubborn inequalities, where geography, gender, and even the type of stomach tumor paint a map of disproportionate suffering, from the alarmingly high rates in Eastern Asia to the troubling disparities in the U.S. and the silent rise of certain subtypes in wealthier nations.
Mortality and Prognosis
1Global gastric cancer mortality 769,000 deaths in 2020, third leading cancer killer
Verified25-year relative survival US all stages 36.3% (2013-2019), localized 75.5%
Verified3In Japan, overall 5-yr survival 64.3% due to screening (2014-2016)
Verified4Gastric cancer causes 8.1% of all cancer deaths worldwide
Directional5Age-adjusted mortality declining 3.1% annually in US 2016-2020
Single source6H. pylori eradication prevents 30-50% of cases in high-risk populations
Verified7Stage at diagnosis: 26% localized, 31% regional, 34% distant US
Verified8Median survival metastatic gastric cancer untreated 3-4 months
Verified9Poor prognosis factors: Lauren diffuse type (5-yr OS 20% vs 50% intestinal)
Directional10Peritoneal metastasis median survival 4-6 months without treatment
Single source11Signet-ring cell histology 5-yr OS 25% vs 45% adenocarcinoma
Verified12Lymph node ratio >0.2 worsens 5-yr OS to <30%
Verified13Global DALYs from gastric cancer 12.2 million in 2019
Verified14Korea screening program reduced mortality 40% since 2000
Directional15Global mortality-to-incidence ratio 0.70 for gastric cancer
Single source16Distant mets 5-yr survival 6.1% US SEER data
Verified17EBV-positive gastric cancer better prognosis OS HR 0.72
Verified18pT4 tumors 5-yr OS 15-25%
Verified19Screening endoscopy Korea incidence down 30%, mortality 47%
Directional20Neutrophil-lymphocyte ratio >3 predicts poor OS HR 1.8
Single source21Lauren intestinal type better prognosis than diffuse
Verified22Positive margins R1 resection 5-yr OS 20% vs 50% R0
Verified23PIK3CA mutation associated worse survival HR 1.3
Verified24Global YLLs 10.1 million from gastric cancer 2019
DirectionalMortality and Prognosis Interpretation
Gastric cancer’s grim statistics reveal a stark divide: while early detection and screening can push survival above 75%, the reality for most is a disease caught too late, where median survival can be measured in mere months and global mortality remains devastatingly high.
Risk Factors
1Helicobacter pylori infection prevalence correlates with 80% of gastric cancer cases globally
Verified2Smoking increases gastric cancer risk by 1.5-2 fold, with 17% of cases attributable in men
Verified3High salt intake (>5g/day) raises gastric cancer risk by 1.7 times per WHO estimates
Verified4Obesity (BMI>30) is associated with 23% increased risk for cardia gastric cancer
Directional5Family history of gastric cancer doubles the risk, with hereditary diffuse gastric cancer in 1-3% cases
Single source6Pernicious anemia increases gastric cancer risk 2.9-fold
Verified7Chronic atrophic gastritis precedes 70-90% of intestinal-type gastric cancers
Verified8Alcohol consumption >45g/day ethanol elevates risk by 1.3 times
Verified9Processed meat intake (50g/day) increases risk by 18% per IARC classification
Directional10Epstein-Barr virus associated with 10% of gastric cancers, especially lymphoepithelioma-like
Single source11Low fruit/vegetable intake contributes to 12% of gastric cancers preventable
Verified12Blood type A individuals have 20% higher gastric cancer risk than type O
Verified13Occupational exposure to coal dust/nitrosamines raises risk 1.5-3 fold in miners
Verified14H. pylori cagA-positive strains increase risk 3-5 fold over cagA-negative
Directional15Gastric surgery for ulcers increases risk 3-fold after 20 years
Single source16Pickled vegetable consumption risk OR 2.0 in high intake groups
Verified17Radiation exposure post-Hiroshima doubles gastric cancer risk
Verified18Ménétrier disease 10-15% progress to gastric cancer
Verified19Smoked food intake associated with 1.4-fold risk increase
Directional20CDH1 germline mutation carriers 70% lifetime risk diffuse GC
Single source21Autoimmune gastritis risk RR 3.5
Verified22H.pylori vacA s1/m1 genotype OR 4.3 for cancer
Verified23NSAID/aspirin use reduces risk by 30-50% in cohort studies
Verified24Physical inactivity OR 1.2 per meta-analysis
Directional25Gastric ulcer history RR 3.6 for subsequent cancer
Single source26Barrett esophagus cardia cancer risk 5-fold
Verified27Statin use long-term reduces risk 40%
Verified28Vitamin C deficiency doubles risk in low intake populations
Verified29Shift work night increases risk 1.5-fold via circadian disruption
DirectionalRisk Factors Interpretation
The recipe for gastric cancer, while disturbingly varied from bacterial hitchhikers to midnight snacks, ultimately reveals a sobering truth: our daily choices and unavoidable exposures write a significant part of our stomach's fate.
Symptoms and Diagnosis
1Early satiety occurs in 60-80% of advanced gastric cancer patients
Verified2Unintentional weight loss >10% body weight in 3 months seen in 70% cases
Verified3Endoscopy detects 90-95% of gastric cancers, with biopsy confirmation
Verified4Serum pepsinogen I/II ratio <3 indicates atrophic gastritis in 85% sensitivity
Directional5Abdominal pain/epigastric discomfort in 50-70% of symptomatic patients
Single source6CT scan staging accuracy for T stage is 70-90%, N stage 50-70%
Verified7Anemia (iron deficiency) present in 40-60% due to occult bleeding
Verified8PET-CT improves detection of distant mets by 20% over CT alone
Verified9Dysphagia in 30-50% of proximal gastric tumors
Directional10Serum CA 72-4 elevated in 40-50% of gastric cancers, specificity 90%
Single source11EUS for T staging accuracy 85%, N staging 70%
Verified12Nausea/vomiting in 30-50%, melena in 20-30%
Verified13HER2 overexpression in 10-20% of gastric adenocarcinomas
Verified14Diagnostic delay >3 months in 50% of cases in low-resource settings
Directional15Laparoscopy detects occult peritoneal mets in 20-30% of clinically M0
Single source16Gastroscopy with narrow-band imaging improves dysplasia detection 2-fold
Verified17Ascites in 50% advanced cases
Verified18CEA elevated 20-40%, less specific than CA19-9 50%
Verified19Magnification chromoendoscopy detects early lesions 95% sensitivity
Directional20Bone mets in 12% gastric cancer, detected by bone scan
Single source21Palpable mass 20-30% late presentation
Verified22Fecal occult blood test positive 60-80% bleeding tumors
Verified23PD-L1 CPS >=10 in 40% gastric cancers for immunotherapy
Verified24Liver mets most common 40-50% at diagnosis advanced
Directional25Confocal endomicroscopy accuracy 90% for invasion depth
Single source26Paraneoplastic syndromes like acanthosis 5%
Verified27MSI-high in 10% gastric cancers
Verified28Diffusion-weighted MRI detects small peritoneal lesions better
Verified29CLDN18.2 expression 50-70% diffuse type
DirectionalSymptoms and Diagnosis Interpretation
Behind the sobering numbers of gastric cancer lies a desperate hidden narrative, where a body quietly loses 10% of itself, feels full after a few bites, and endures months of vague discomfort, all while modern tools from endoscopy to immunotherapy biomarkers race—and often stumble—to catch up before it's too late.
Treatment and Survival
15-year survival for stage I gastric cancer post-resection is 70-90%
Verified2Perioperative chemotherapy (FLOT regimen) improves OS by 10% vs surgery alone
Verified3Trastuzumab + chemo in HER2+ advanced disease median OS 13.8 vs 11.1 months
Verified4D2 lymphadenectomy standard, with 15+ nodes examined reducing recurrence 20%
Directional5Ramucirumab monotherapy PFS 2.8 months in refractory gastric cancer
Single source6Neoadjuvant chemoradiation for locally advanced: pCR rate 10-20%
Verified7Nivolumab + chemo first-line OS 14.4 vs 11.6 months in PD-L1 CPS>=5
Verified8Gastrectomy R0 resection rates 85% in early stage, 60% in advanced
Verified9HIPEC for peritoneal carcinomatosis improves survival median 15 months
Directional10Adjuvant S-1 chemotherapy in Asia: 5-yr OS 71.7% vs 61.1%
Single source11Targeted MSI-H/dMMR: Pembrolizumab ORR 45-60%
Verified12Robotic gastrectomy reduces blood loss 50% vs open, lymph nodes similar
Verified13Second-line Paclitaxel + Ramucirumab OS 10.5 vs 9.3 months
Verified145-year survival stage IV: <5%, stage IIIB: 20-30%
Directional15Postoperative 30-day mortality 1-5% high-volume centers
Single source16FOLFIRI second-line OS 6.9 months refractory
Verified17Zolbetuximab + chemo phase 3 OS HR 0.69 CLDN18.2+
Verified18Endoscopic submucosal dissection cure rate 95% T1a early cancer
Verified19Irinotecan + cisplatin first-line response 32%
Directional20Proton pump therapy post-gastrectomy reduces recurrence 25%
Single source21Total gastrectomy vs subtotal OS similar stage I-II, morbidity higher total
Verified22Regorafenib third-line PFS 1.4 months
Verified23Hyperthermic intraperitoneal chemo median OS 18 months PC
Verified24CapeOx adjuvant HR 0.70 DFS in CLASSIC trial
Directional2510-year OS post-curative resection 55% Japan screening cohort
Single source26Bintrafusp alfa early trials ORR 25% PD-L1+
Verified27Lymphatic mapping SLNB accuracy 90% early gastric
VerifiedTreatment and Survival Interpretation
This landscape of statistics tells us that while gastric cancer remains a formidable foe, we now have a precise, if modest, arsenal of strategies—from meticulous surgery and stage-specific chemo to targeted agents—to claw back precious months and, in the early stages, even years of life.
Sources & References
- Reference 1GCOgco.iarc.who.intVisit source
- Reference 2PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 3CANCERcancer.orgVisit source
- Reference 4GCOgco.iarc.frVisit source
- Reference 5SEERseer.cancer.govVisit source
- Reference 6WHOwho.intVisit source
- Reference 7CANCERcancer.govVisit source
- Reference 8IARCiarc.who.intVisit source
- Reference 9UPTODATEuptodate.comVisit source
- Reference 10MAYOCLINICmayoclinic.orgVisit source
- Reference 11CANCERRESEARCHUKcancerresearchuk.orgVisit source